331. 特発性多中心性キャッスルマン病 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 33 / 薬物数 : 41 - (DrugBank : 21) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 123
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
Best Supportive Care (BSC)
Janssen Research & Development, LLC
2010 Phase 2 NCT01024036 Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Jordan;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Poland;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
Bevacizumab
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States;
Bortezomib
National Cancer Institute (NCI)
2004 Phase 2 NCT00092222 United States;
Peking Union Medical College Hospital
2019 Phase 2 NCT03982771 China;
CNTO 328
Centocor, Inc.
2005 Phase 1 NCT00412321 United States;
CNTO328
Centocor BV
2010 Phase 2 EUCTR2009-012380-34-FR Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2009-012380-34-ES Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen Biologics B.V.
2010 Phase 2 EUCTR2009-012380-34-NL Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen Biologics BV
2010 - EUCTR2009-012380-34-HU Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen-Cilag International N.V.
2010 - EUCTR2009-012380-34-DE Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen-Cilag International N.V.
2013 Phase 2 EUCTR2010-022837-27-GB Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States;
2012 Phase 2 EUCTR2010-022837-27-ES Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States;
2012 Phase 2 EUCTR2010-022837-27-DE Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States;
2012 Phase 2 EUCTR2010-022837-27-BE Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States;
2010 Phase 2 EUCTR2009-012380-34-GB Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
2010 Phase 2 EUCTR2009-012380-34-BE Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
CX-4945 oral formulation
Cylene Pharmaceuticals
2009 Phase 1 NCT00891280 United States;
Cetuximab
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States;
Chimeric murine human anti-IL-6 monoclonal antibody
Centocor BV
2010 Phase 2 EUCTR2009-012380-34-FR Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2009-012380-34-ES Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen Biologics B.V.
2010 Phase 2 EUCTR2009-012380-34-NL Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen Biologics BV
2010 - EUCTR2009-012380-34-HU Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen-Cilag International N.V.
2010 - EUCTR2009-012380-34-DE Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen-Cilag International N.V.
2010 Phase 2 EUCTR2009-012380-34-GB Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
2010 Phase 2 EUCTR2009-012380-34-BE Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
Cyclophosphamide
Fred Hutchinson Cancer Research Center
2019 Phase 1 NCT03864419 Uganda;United States;
National Cancer Institute (NCI)
2014 Phase 1/Phase 2 NCT02228512 United States;
2004 Phase 2 NCT00092222 United States;
Peking Union Medical College Hospital
2019 Phase 2 NCT03982771 China;
Dexamethason
Peking Union Medical College Hospital
2019 Phase 2 NCT03982771 China;
Doxorubicin
National Cancer Institute (NCI)
2014 Phase 1/Phase 2 NCT02228512 United States;
Doxorubicin Hydrochloride
Fred Hutchinson Cancer Research Center
2019 Phase 1 NCT03864419 Uganda;United States;
Etoposide
Fred Hutchinson Cancer Research Center
2019 Phase 1 NCT03864419 Uganda;United States;
National Cancer Institute (NCI)
2014 Phase 1/Phase 2 NCT02228512 United States;
2004 Phase 2 NCT00092222 United States;
UNC Lineberger Comprehensive Cancer Center
2021 Phase 2 NCT04585893 Malawi;
Filgrastim (G-CSF)
National Cancer Institute (NCI)
2004 Phase 2 NCT00092222 United States;
Interferon-alpha
National Cancer Institute (NCI)
2004 Phase 2 NCT00092222 United States;
Lenalidomide
Department of Hematology, Jiangsu Provincial People's Hospital
2021 Phase 4 ChiCTR2100048364 China;
Liposomal Doxorubicin
National Cancer Institute (NCI)
2004 Phase 2 NCT00092222 United States;
Methotrexate
Fred Hutchinson Cancer Research Center
2019 Phase 1 NCT03864419 Uganda;United States;
Nelfinavir
Sidney Kimmel Comprehensive Cancer Center
2014 Phase 0 NCT02080416 United States;
Pomalidomide
National Cancer Institute (NCI)
2014 Phase 1/Phase 2 NCT02228512 United States;
Prednisone
Fred Hutchinson Cancer Research Center
2019 Phase 1 NCT03864419 Uganda;United States;
National Cancer Institute (NCI)
2014 Phase 1/Phase 2 NCT02228512 United States;
2004 Phase 2 NCT00092222 United States;
Rituximab
Department of Hematology, Jiangsu Provincial People's Hospital
2021 Phase 4 ChiCTR2100048364 China;
French National Agency for Research on AIDS and Viral Hepatitis
2003 Phase 2 NCT00127569 -
National Cancer Institute (NCI)
2014 Phase 1/Phase 2 NCT02228512 United States;
2004 Phase 2 NCT00092222 United States;
UNC Lineberger Comprehensive Cancer Center
2021 Phase 2 NCT04585893 Malawi;
Rituximab and Hyaluronidase Human
Fred Hutchinson Cancer Research Center
2019 Phase 1 NCT03864419 Uganda;United States;
Siltuximab
EusaPharma (UK) Limited
2021 Phase 2 NCT04838860 United States;
Janssen Research & Development, LLC
2011 Phase 2 NCT01400503 Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States;
2010 Phase 2 NCT01024036 Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Jordan;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Poland;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
Sirolimus
Kawakami Atsushi
2020 Phase 2 JPRN-jRCT2071190029 Japan;
National Cancer Institute (NCI)
2004 Phase 2 NCT00092222 United States;
University of Pennsylvania
2019 Phase 2 NCT03933904 United States;
Suramin
University of Arkansas
1995 Phase 2 NCT00002652 United States;
Temsirolimus
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States;
Thalidomide, cyclophosphamide and prednisone
Peking Union Medical College Hospital
2017 Phase 2 NCT03043105 China;
Tocilizumab
National Cancer Institute (NCI)
2011 Phase 2 NCT01441063 United States;
Tocilizumab [RoActemra/Actemra]
Hoffmann-La Roche
2006 Phase 1 NCT01183598 United States;
Valganciclovir
National Cancer Institute (NCI)
2004 Phase 2 NCT00092222 United States;
University of Washington
2008 Phase 4 NCT00361933 United States;
Valganciclovir (VGC)
National Cancer Institute (NCI)
2011 Phase 2 NCT01441063 United States;
Vincristine
Fred Hutchinson Cancer Research Center
2019 Phase 1 NCT03864419 Uganda;United States;
National Cancer Institute (NCI)
2014 Phase 1/Phase 2 NCT02228512 United States;
2004 Phase 2 NCT00092222 United States;
Zanubrutinib
Peking Union Medical College Hospital
2021 Phase 2 NCT04743687 China;
Zidovudine
National Cancer Institute (NCI)
2011 Phase 2 NCT01441063 United States;
2004 Phase 2 NCT00092222 United States;
Janssen Research & Development, LLC
2010 Phase 2 NCT01024036 Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Jordan;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Poland;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
Bevacizumab
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States;
Bortezomib
National Cancer Institute (NCI)
2004 Phase 2 NCT00092222 United States;
Peking Union Medical College Hospital
2019 Phase 2 NCT03982771 China;
CNTO 328
Centocor, Inc.
2005 Phase 1 NCT00412321 United States;
CNTO328
Centocor BV
2010 Phase 2 EUCTR2009-012380-34-FR Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2009-012380-34-ES Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen Biologics B.V.
2010 Phase 2 EUCTR2009-012380-34-NL Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen Biologics BV
2010 - EUCTR2009-012380-34-HU Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen-Cilag International N.V.
2010 - EUCTR2009-012380-34-DE Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen-Cilag International N.V.
2013 Phase 2 EUCTR2010-022837-27-GB Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States;
2012 Phase 2 EUCTR2010-022837-27-ES Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States;
2012 Phase 2 EUCTR2010-022837-27-DE Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States;
2012 Phase 2 EUCTR2010-022837-27-BE Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States;
2010 Phase 2 EUCTR2009-012380-34-GB Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
2010 Phase 2 EUCTR2009-012380-34-BE Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
CX-4945 oral formulation
Cylene Pharmaceuticals
2009 Phase 1 NCT00891280 United States;
Cetuximab
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States;
Chimeric murine human anti-IL-6 monoclonal antibody
Centocor BV
2010 Phase 2 EUCTR2009-012380-34-FR Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2009-012380-34-ES Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen Biologics B.V.
2010 Phase 2 EUCTR2009-012380-34-NL Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen Biologics BV
2010 - EUCTR2009-012380-34-HU Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen-Cilag International N.V.
2010 - EUCTR2009-012380-34-DE Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Janssen-Cilag International N.V.
2010 Phase 2 EUCTR2009-012380-34-GB Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
2010 Phase 2 EUCTR2009-012380-34-BE Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
Cyclophosphamide
Fred Hutchinson Cancer Research Center
2019 Phase 1 NCT03864419 Uganda;United States;
National Cancer Institute (NCI)
2014 Phase 1/Phase 2 NCT02228512 United States;
2004 Phase 2 NCT00092222 United States;
Peking Union Medical College Hospital
2019 Phase 2 NCT03982771 China;
Dexamethason
Peking Union Medical College Hospital
2019 Phase 2 NCT03982771 China;
Doxorubicin
National Cancer Institute (NCI)
2014 Phase 1/Phase 2 NCT02228512 United States;
Doxorubicin Hydrochloride
Fred Hutchinson Cancer Research Center
2019 Phase 1 NCT03864419 Uganda;United States;
Etoposide
Fred Hutchinson Cancer Research Center
2019 Phase 1 NCT03864419 Uganda;United States;
National Cancer Institute (NCI)
2014 Phase 1/Phase 2 NCT02228512 United States;
2004 Phase 2 NCT00092222 United States;
UNC Lineberger Comprehensive Cancer Center
2021 Phase 2 NCT04585893 Malawi;
Filgrastim (G-CSF)
National Cancer Institute (NCI)
2004 Phase 2 NCT00092222 United States;
Interferon-alpha
National Cancer Institute (NCI)
2004 Phase 2 NCT00092222 United States;
Lenalidomide
Department of Hematology, Jiangsu Provincial People's Hospital
2021 Phase 4 ChiCTR2100048364 China;
Liposomal Doxorubicin
National Cancer Institute (NCI)
2004 Phase 2 NCT00092222 United States;
Methotrexate
Fred Hutchinson Cancer Research Center
2019 Phase 1 NCT03864419 Uganda;United States;
Nelfinavir
Sidney Kimmel Comprehensive Cancer Center
2014 Phase 0 NCT02080416 United States;
Pomalidomide
National Cancer Institute (NCI)
2014 Phase 1/Phase 2 NCT02228512 United States;
Prednisone
Fred Hutchinson Cancer Research Center
2019 Phase 1 NCT03864419 Uganda;United States;
National Cancer Institute (NCI)
2014 Phase 1/Phase 2 NCT02228512 United States;
2004 Phase 2 NCT00092222 United States;
Rituximab
Department of Hematology, Jiangsu Provincial People's Hospital
2021 Phase 4 ChiCTR2100048364 China;
French National Agency for Research on AIDS and Viral Hepatitis
2003 Phase 2 NCT00127569 -
National Cancer Institute (NCI)
2014 Phase 1/Phase 2 NCT02228512 United States;
2004 Phase 2 NCT00092222 United States;
UNC Lineberger Comprehensive Cancer Center
2021 Phase 2 NCT04585893 Malawi;
Rituximab and Hyaluronidase Human
Fred Hutchinson Cancer Research Center
2019 Phase 1 NCT03864419 Uganda;United States;
Siltuximab
EusaPharma (UK) Limited
2021 Phase 2 NCT04838860 United States;
Janssen Research & Development, LLC
2011 Phase 2 NCT01400503 Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States;
2010 Phase 2 NCT01024036 Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Jordan;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Poland;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
Sirolimus
Kawakami Atsushi
2020 Phase 2 JPRN-jRCT2071190029 Japan;
National Cancer Institute (NCI)
2004 Phase 2 NCT00092222 United States;
University of Pennsylvania
2019 Phase 2 NCT03933904 United States;
Suramin
University of Arkansas
1995 Phase 2 NCT00002652 United States;
Temsirolimus
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States;
Thalidomide, cyclophosphamide and prednisone
Peking Union Medical College Hospital
2017 Phase 2 NCT03043105 China;
Tocilizumab
National Cancer Institute (NCI)
2011 Phase 2 NCT01441063 United States;
Tocilizumab [RoActemra/Actemra]
Hoffmann-La Roche
2006 Phase 1 NCT01183598 United States;
Valganciclovir
National Cancer Institute (NCI)
2004 Phase 2 NCT00092222 United States;
University of Washington
2008 Phase 4 NCT00361933 United States;
Valganciclovir (VGC)
National Cancer Institute (NCI)
2011 Phase 2 NCT01441063 United States;
Vincristine
Fred Hutchinson Cancer Research Center
2019 Phase 1 NCT03864419 Uganda;United States;
National Cancer Institute (NCI)
2014 Phase 1/Phase 2 NCT02228512 United States;
2004 Phase 2 NCT00092222 United States;
Zanubrutinib
Peking Union Medical College Hospital
2021 Phase 2 NCT04743687 China;
Zidovudine
National Cancer Institute (NCI)
2011 Phase 2 NCT01441063 United States;
2004 Phase 2 NCT00092222 United States;